2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 90

Physical Function, Pain and Fatigue Are Related to Sleep Disturbance in Females with Rheumatoid Arthritis
Abstract Number: 2061

Physician Variation in Documentation of Rheumatoid Arthritis Quality Measures and Evaluation of Relationship with Radiographic Progression
Abstract Number: 79

Physician’s Global Assessment Is Affected by Physician’s Age and Gender, but Not by Patient Age and Gender in Rheumatoid Arthritis Patients Treated in Routine Care. Data From the Danish Nationwide Danbio Registry
Abstract Number: 1083

Physicians’ Recommendations for Total Knee Arthroplasty in Younger Persons with Moderate Osteoarthritis
Abstract Number: 2086

PI3-Kinase Controls Inflammatory Bone Destruction by Regulating the Osteoclastogenic Potential of Myeloid Cells
Abstract Number: 451

Pilot Study of Stimulation of the Cholinergic Anti-Inflammatory Pathway with an Implantable Vagus Nerve Stimulation Device in Patients with Rheumatoid Arthritis
Abstract Number: 1530

Plasma Cell Analysis As a Biomarker for Disease Activity in Patients with Granulomatosis with Polyangiitis
Abstract Number: 888

Plasma Cells Express the Novel Cytokine Interleukin-36α in Psoriatic and Rheumatoid Arthritis Synovium
Abstract Number: 2122

Plasma chemerin as a Useful Marker for Disease Activity in Patients with Rheumatoid Arthritis
Abstract Number: 2348

Plasma Fibrinogen Better Identifies Persistent Disease Activity in Polymyalgia Rheumatica Than Either ESR or CRP
Abstract Number: 2382

Plasma Fibrinogen is an Accurate Marker of Disease Activity in Patients with Polymyalgia Rheumatica
Abstract Number: 680

Plasma Level of Galectin-3 Binding Protein Reflects Type I Interferon Activity and Is Highly Increased in Patients with Systemic Lupus Erythematosus
Abstract Number: 1495

Platelet Aggregability, Eicosanoid Biosynthesis and Oxidative Stress in Primary Raynaud’s Phenomenon and Systemic Sclerosis
Abstract Number: 2296

Platelet Release Products Mediate Endothelial Apoptosis: A Possible Role for Thrombospondin 1- CD36 Pathway in SSc-Endothelial Apoptosis
Abstract Number: 2500

Podocyte Injury in Membranous and Proliferative Lupus Nephritis: Distinct Underlying Mechanisms?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].